Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
OpenAI Restricts Astra AI Over Cyberattack Risks 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
LIVONIA, Mich., March 08, 2018 -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia, non-alcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), today announced that management will be making presentations at the 30th Annual ROTH Conference and the H.C. Wainwright 2nd Annual NASH Investor Conference.
| Presentation Details 30th Annual ROTH Conference | ||
| Date: Time: Panel: Panelist: Location: | Tuesday, March 13 7am Pacific Time/10am Eastern Time It Is Not a Myth, It Is Real: Pediatric NASH Seth Reno, Chief Commercial Officer Ritz Carlton, Laguna Niguel, California | |
| Date: Time: Panel: Panelist: Location: | Tuesday, March 13 8am Pacific Time/11am Eastern Time Love Your Liver, Love Your Heart: Cardio-Metabolic Molecules Steve Gullans, Ph.D., Interim Chief Executive Officer Ritz Carlton, Laguna Niguel, California | |
| H.C. Wainwright 2nd Annual NASH Investor Conference | ||
| Date: Time: Presenter: Location: Webcast: | Monday, March 19 8:40am Eastern Time Steve Gullans, Ph.D., Interim Chief Executive Officer St. Regis Hotel, New York City http://wsw.com/webcast/hcw3/gemp/ | |
About Gemphire
Gemphire is a clinical-stage biopharmaceutical company that is committed to helping patients with cardiometabolic disorders, including dyslipidemia and NASH. The Company is focused on providing new treatment options for cardiometabolic diseases through its complementary, convenient, cost-effective product candidate gemcabene as add-on to the standard of care, especially statins, that will benefit patients, physicians, and payors. Gemphire’s Phase 2 clinical program is evaluating the efficacy and safety of gemcabene in hypercholesterolemia, including FH and ASCVD, SHTG and NASH/NAFLD. Two trials supporting hypercholesterolemia have been completed under NCT02722408 and NCT02634151. Gemphire has completed recruitment for a clinical trial for SHTG under NCT02944383, and has initiated separate trials for adult NASH and pediatric NAFLD. Please visit www.gemphire.com for more information.
Contact:
Andrew McDonald, Ph.D.
LifeSci Advisors, LLC
(646) 597-6987
Jeff Mathiesen, CFO
Gemphire Therapeutics Inc.
(734)-245-1700
